Nova Leap HealthNVLPF 50 ROE % is 6.82% as of Mar. 2026. GuruFocus rates NVLPF with a GF Score™ of 50/100 and a GF Value™ of $0.19 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Nova Leap Health ranks worse than 65.29% on this metric.
The historical rank and industry rank for Nova Leap Health's ROE % or its related term are showing as below:
NVLPF'
s ROE % Range Over the Past 10 Years
Min: -338.86 Med: -5.16 Max: 14.68
Current: 1.15
During the past 10 years, Nova Leap Health's highest ROE % was 14.68%. The lowest was -338.86%. And the median was -5.16%.
NVLPF's ROE % is ranked worse than 65.29% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs NVLPF: 1.15
Nova Leap Health (OTCPK:NVLPF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Nova Leap Health ROE % Related Terms
Nova Leap Health ROE % Historical Data
* Premium members only.
The historical data trend for Nova Leap Health's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Nova Leap Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Leap Health ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nova Leap Health's ROE % distribution charts can be found below:
* The bar in red indicates where Nova Leap Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Nova Leap Health (NVLPF) has a ROE % of 6.82% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nova Leap Health and its competitors. According to the industry distribution chart, Nova Leap Health ranks #410 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 65.3%.
Is Nova Leap Health's ROE % too high?
Nova Leap Health's current ROE % is 6.82%. The Healthcare Providers & Services industry median ROE % is 5.72. Nova Leap Health's value of 6.82% is 19.2% above this industry median. Based on the distribution chart, Nova Leap Health ranks #410 out of 628 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Nova Leap Health has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nova Leap Health's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nova Leap Health ranks #410 out of 628 companies for ROE %. This places Nova Leap Health in the lower half of its industry. The industry median ROE % is 5.72. Nova Leap Health's value of 6.82% is 19.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Leap Health's current ROE % of 6.82% is 19.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nova Leap Health and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Leap Health's current ROE % is 6.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Leap Health stock overvalued right now?
Based on GuruFocus' analysis, Nova Leap Health (NVLPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.25 — trading 29.7% above its estimated fair value. The current ROE % is 6.82% and 19.2% above the Healthcare Providers & Services industry median of 5.72. Nova Leap Health's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Nova Leap Health (NVLPF), the current ROE % is 6.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Leap Health (NVLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Leap Health stock appears to be overvalued.
The current stock price of $0.25 is trading 29.7% above its estimated GF Value™ of $0.19.
GuruFocus considers Nova Leap Health to be Modestly Overvalued.
Key valuation signals for NVLPF:
ROE %: 6.82%
GF Value™: $0.19 vs. price of $0.25 (29.7% above fair value)
Industry Position: 19.2% above the Healthcare Providers & Services median (#410 of 628)
No single metric tells the full story. See the NVLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Leap Health Corp operates in the healthcare industry. The company is a provider of home and home health care services to clients..The principal business activities of the company and its subsidiaries are to provide skilled and non-medical home care to clients. Its service offerings include meal preparation, housekeeping, transportation, personal care, and medication reminders. Its segments comprise Canadian and U.S. operations. The company derives a majority of its revenue from the United States.
50GF Score
Get the complete analysis for NVLPF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVLPF has been successfully added to your 
